

Navigating Real World Evidence in the Management of Advanced Breast Cancer: Insights for Pharmacists

Patient Assistance for Biomarker Testing

Resources and References

ESMO 2019 https://oncologypro.esmo.org/content/download/231866/3921680/version/1/file/WORLDGI2019_20_schrag.pdf

AACR 2019

https://www.aacr.org/AdvocacyPolicy/GovernmentAffairs/Documents/FDA-AACR_RWE_SlideDeck.pdf

FDA Webinar May 15, 2019

Slides: <https://www.fda.gov/media/123160/download>

Webinar: <https://concerted.adobeconnect.com/pi3e4hxqia9/?proto=true>

FDA Drug Approvals

<https://www.fda.gov/patients/learn-about-drug-and-device-approvals/fast-track-breakthrough-therapy-accelerated-approval-priority-review>

<https://www.fda.gov/drugs/development-approval-process-drugs/how-drugs-are-developed-and-approved>

<https://www.fda.gov/regulatory-information/selected-amendments-fdc-act/21st-century-cures-act>

Other References:

1. Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence – what is it and what can it tell us? *N Engl J Med* 2016;375(23):2293-7.
2. Lee J and Little TD. A practical guide to propensity score analysis for applied clinical research. *Behav Res Therapy* 2017;98:76-90.
3. Mougalian SS, Copher R, Kish JK, et al. Clinical benefit of treatment with eribulin mesylate for metastatic triple-negative breast cancer: long-term outcomes of patients treated in the US community oncology setting. *Cancer Med* 2018;7:4371-8.
4. Kish JK, Ward MA, Garofalo D, et al. Real-world evidence analysis of Palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval. *Br Cancer Res* 2018;20 (37):1-8.
5. Varella L, Eziokwu AS, Jia X, et al. Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with Palbociclib and endocrine therapy. *Br Cancer Res Treat* 2019;176:429-34.
6. Mazzotta M, Krasniqi E, Barchiesi G, et al. Long-term safety and real-world effectiveness of Trastuzumab in breast cancer. *J Clin Medicine* 2019;8(254):1-18.
7. Halaven (eribulin) product information. Eisai Inc. Woodcliff Lake, NJ. December 2017. <https://www.halaven.com/-/media/Files/Halaven/HALAVEN-Full-Prescribing-Information.pdf>
8. Mougalian SS, Copher R, McAllister L, et al. Outcomes of real-world use of eribulin plus trastuzumab for HER2-positive metastatic breast cancer (Abstract poster P6-17-28). San Antonio Breast Cancer Symposium 2018 https://www.abstracts2view.com/sabcs/view.php?nu=SABCS18L_223&terms=
9. Ibrance (Palbociclib) product information. Pfizer Labs. New York, NY. September 2019.
10. <http://labeling.pfizer.com/ShowLabeling.aspx?format=PDF&id=2191>
11. Bartlett CH, Mardekian J, Yu-Kite M, et al. Real-world evidence of male breast cancer (BC) patients treated with palbociclib (PAL) in combination with endocrine therapy (ET) (Abstract).
12. DOI: 10.1200/JCO.2019.37.15_suppl.1055 *Journal of Clinical Oncology* 37, no.15_suppl (May 20, 2019) 1055-1055.